Advanced glycation end products and diabetic cardiovascular disease

Anand Prasad, Peter Bekker, Sotirios Tsimikas

Research output: Contribution to journalReview articlepeer-review

121 Scopus citations


Advanced glycation end products (AGEs) are formed by a nonenzymatic reaction of sugar moieties (eg, glucose, fructose, glycolytic adducts) with the free amino groups on amino acid residues of proteins. A growing body of data demonstrate that AGEs are intimately involved in the pathophysiology of cardiovascular disease by stimulating inflammation, contributing to atheroma formation, and modulating vascular stiffness. The role of AGEs as potential biomarkers for disease presence and prognosis in patients with diabetes mellitus remains an active area of study. Epidemiologic and angiographic studies suggest that AGE levels may be related to the presence and extent of atherosclerosis, and may predict future outcomes in select populations. The present review summarizes the relevant evidence supporting the role of advanced glycation in promoting atherosclerosis and the epidemiologic studies demonstrating an association between AGEs and diabetic cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)177-183
Number of pages7
JournalCardiology in review
Issue number4
StatePublished - Jul 2012


  • advanced glycation
  • atherosclerosis
  • diabetes mellitus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Advanced glycation end products and diabetic cardiovascular disease'. Together they form a unique fingerprint.

Cite this